Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 179

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study

Dogra, Sunil, Beydoun, Said, Mazzola, Jennifer, Hopwood, Margaret, Wan, Ying·2005·European Journal of Pain

Abstract

In this multicentre, placebo‐controlled, 16‐week trial, the efficacy and safety of oxcarbazepine monotherapy in patients with neuropathic pain of diabetic origin was evaluated. Eligible patients had a 6‐month to 5‐year history of neuropathic pain symptoms of diabetic origin and a pain rating of ≥50 units on the visual analogue scale (VAS). Oxcarbazepine was initiated at a dose of 300 mg/day and titrated to a maximum dose of 1800 mg/day. In total, 146 patients (oxcarbazepine, n = 69; placebo, n = 77) were randomized. After 16 weeks, oxcarbazepine‐treated patients experienced a significantly larger decrease in the average change in VAS score from baseline compared with placebo (‐24.3 vs. −14.7 units, respectively; p = 0.01). The reduction from baseline in mean VAS score for oxcarbazepine‐treated patients was of a greater magnitude than placebo as early as week 2 (‐8.0 vs. −4.7; p < 0.05). A significantly greater proportion of oxcarbazepine‐treated patients experienced a >50% reduction from baseline in VAS score at the end of treatment compared with placebo (35.2% vs. 18.4%, respectively; p = 0.0156; number needed to treat = 6.0). Global assessment of therapeutic effect rating was improved in more oxcarbazepine patients than placebo patients (48% vs. 22%, respectively; p = 0.0025). Patients on oxcarbazepine were awakened less frequently due to pain than patients on placebo. Most adverse events were mild to moderate in severity, transient, and in line with the known tolerability profile of oxcarbazepine. These observations suggest that oxcarbazepine monotherapy, pending additional trials, may be efficacious and may provide clinically meaningful pain relief in patients with neuropathic pain of diabetic origin.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ejpain.2004.11.006

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 179

Metadata

Authors
Dogra, S., Beydoun, S., Mazzola, J., Hopwood, M., & Wan, Y.
Venue
European Journal of Pain
Publisher
Wiley
Published
2005-10
Volume
9
Issue
5
Pages
543-543
ISSN
  • 1090-3801 (ISSN-L)
  • 1532-2149
OpenAlex
W1990660816
Cited by
179
References
5
FWCI
8.17
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. https://app.cochat.ai/papers/10.1016/j.ejpain.2004.11.006
The paper
Dogra, S., Beydoun, S., Mazzola, J., Hopwood, M., & Wan, Y. (2005). Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Pain. https://doi.org/10.1016/j.ejpain.2004.11.006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.